Ionis Pharmaceuticals Inc (IONS)

Ionis Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on RNA-targeted medicines in the United States. Its marketed products include TRYNGOLZA for adults with familial chylomicronemia syndrome and acute pancreatitis risk, DAWNZERA for hereditary angioedema prevention, WAINUA for hereditary transthyretin-mediated amyloidosis polyneuropathy, SPINRAZA for spinal muscular atrophy, QALSODY for amyotrophic lateral sclerosis, TEGSEDI for ATTRv-PN, and WAYLIVRA for familial chylomicronemia syndrome and familial partial lipodystrophy. The company also has a development pipeline that includes late-stage candidates such as Olezarsen, Zilganerse, and ION582, along with additional investigational programs including Eplontersen, Pelacarsen, Bepirovirsen, Sefaxersen, and Ulefnersen. Ionis maintains strategic collaborations with Biogen and licensing or collaboration agreements with GSK, AstraZeneca, Novartis, Roche, and Metagenomi. Incorporated in 1989 and headquartered in Carlsbad, California, Ionis trades on NASDAQ as common stock under the ticker IONS.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.